NR and Parkinson’s Disease: NADPARK, NR-SAFE and NOPARK
NR and Parkinson’s disease: NOPARK 2026 results, NADPARK, NR-SAFE, clinical scales, dose limits and what the evidence means for care.
Evidence library 14 analyses
Evidence on nicotinamide riboside (NR), NAD+ biology, human trials, dosing, safety and comparisons with other precursors.
Complete library
Browse every published guide, review and evidence update in this topic.
NR and Parkinson’s disease: NOPARK 2026 results, NADPARK, NR-SAFE, clinical scales, dose limits and what the evidence means for care.
NR for brain health and Alzheimer’s: MCI trial results, pTau217, brain NAD+, perfusion, cognition, combinations and what remains unproven.
NR for weight loss, insulin resistance and fatty liver: randomized human findings, cohort overlap, combination trials and limits of metabolic claims.
NR with resveratrol, pterostilbene, TMG and quercetin: randomized findings, methylation evidence, combination safety and the limits of synergy claims.
NR and cancer examined: breast-cancer animal findings, pancreatic-cancer models, human evidence gaps, nicotinamide confusion and treatment discussions.
NR food sources assessed through analytical studies: milk, plant foods, measured quantities, microgram conversions and the limits of supplement comparisons.
NR chloride, hydrogen malate, tartrate and NRH compared: salt identity, label amounts, human evidence, nonclinical safety and current product forms.
Liposomal NR examined: delivery systems, oral-human evidence, mouse IV studies, absorption multipliers, dose comparisons, storage and value.
NR vs niacinamide and niacin: molecule names, NAD+ pathways, flushing, cholesterol, skincare, cancer-prevention evidence and practical choices.